Tag Archives: NIH

The Golden Goose Awards

Politicians sometimes deride research based on the what they perceive as being “silly” titles of federal funded grants.  If they spot a title that deals with “games”, for example, they may assume it deals with some sort of amusement of little value to society, instead of a deep, powerful branch of mathematics that describes the behavior of competing rational agents with much relevance to voting, economics, cooperation, and so on.  Animal rights activists also enjoy the hobby.  The latest example is IDA’s list of “ridiculous research” ,whose claims were sadly repeated by far too many news journalists who were clearly too lazy check if they were accurate.  There were some honorable exceptions, notably an excellent editorial entitled “When the facts ruin a good spin” in the Times Union, which discusses a project on the role of music as a conditioning stimulus for drug use ends with a statement with which we heartily agree:

What’s “ridiculous,” to borrow the press release’s language, is that we fall for it, over and over, egged on by politicians eager to score easy points. And what’s “wasteful” is the time and energy that could be so much better spent on something other than a cheap shot.”

Back in 1976 the House Committee on Appropriations asked the National Science Foundation “Why does the Foundation persist in supporting research whose results have no apparent value to the American people?“  The NSF responded in part that:

Basic research seeks an understanding  of the laws of nature  without  initial  regard  for specific  utilitarian  value. Ultimately, however, it  is of the  most important  practical significance, because in a broad sense it is the foundation upon  which rests  all technological development.  Applied research builds on the results of basic research, seeking detailed  information  about  a specific situation  whose general laws have  been  discovered by  basic  research.  The  final step  toward  utilization  of research-development is  the systematic  application  of knowledge to  the  design  of  end products. [...]

As we  increase  our  knowledge  of nature  and  mankind,  in order  to adjust  nature  to our survival, safety,  comfort and convenience, we must  depend  upon  scientific research  to clarify the  relationships  of many, many things.  Thus,  we study  atoms,  even  though  they  will never  be seen  by an  unaided  human  eye.  We study  stars  too  faint  to  be  seen without  a  telescope  and  with  wavelengths  which  can  only be  detected  with  radio  receivers  or  photographic  plates. To  understand  geology, we must  look  at  geologic formations  and processes in many  parts  of the world where different  conditions have existed.  To understand  more about the  phenomena  of life, we must  study  the  behavior  of viruses,  single  cells,  plants,  and  animals  of  many  species.

A book was compiled covering various areas of research with Isaac Asimov writing an essay defending the value of basic research.

Thus, it was with some surprise and delight that we read in the news about Rep. Jim Cooper (D-Tenn) understanding the value of basic research.  The Washington Post reports that:

On Wednesday afternoon, Cooper rose to the defense of taxpayer-funded research into dog urine, guinea pig eardrums and, yes, the reproductive habits of the parasitic flies known as screwworms–all federally supported studies that have inspired major scientific breakthroughs.

Together with two colleagues he created the Annual Golden Goose Awards to honor federally funded research  “whose work may once have been viewed as unusual, odd, or obscure, but has produced important discoveries benefiting society in significant ways.”

Studying dog urine, among other stuff deem crazy by animal rights cranks, led to major medical discoveries

The article goes on to describe how research on dog urine led to an understanding of the effects of hormones on the human kidney, how studies in the guinea pig led to a treatment for hearing loss in infants, and how studies on the screwworm led to the effective control of the a deadly parasite that targets cattle.  All these provide additional examples refuting the notion that learning about life processes from animals cannot yield knowledge applicable to human health.

The Golden Goose Award has the backing of the American Association for the Advancement of ScienceAssociation of American Universities (who in 2011 published a series of “Scientific Inquirer” articles skewering dubious politically-motivated attacks on basic science) and the Progressive Policy Institute, who are to be congratulated for this excellent initiative to highlight the importance of basic research.

At the press conference to launch the award Rep. Robert Dold told reporters that “When we invest in science, we also invest in jobs. Research and development is a key part to any healthy economy,” while  Rep. Charlie Dent (R-Penn.) added “It’s critical, and the federal government has an important role to play,” who went on to describe how injecting horses with snake venom might “seem peculiar” but led to the discovery of the first anti-venom.

Taking us, once again, to the concluding words of Asimov’s essay:

Unless we continue with science and gather knowledge, whether or not it seems useful on the spot, we will be buried under our problems and find no way out.  Today’s science is tomorrow’s solution — and tomorrow’s problems , too — and, most of all, it is mankind’s greatest adventure, now and forever.

A welcome end to random-source dog and cat dealers

The National Institutes of Health has announced that starting October 1, 2012, NIH funds may no longer be used to buy cats from Class B dealers. A similar prohibition in the purchase of dogs from Class B dealers takes effect in 2015.

Although dogs and cats constitute only small percentage of research animals, they have been used in American biomedical research for over a century for studies of cardiovascular and neurological diseases, and for other areas of research including recent studies that led to a gene therapy for the eye disease Leber’s congenital amaurosis, whose success was reported widely last week.  The use of these animals is tightly regulated by the Animal Welfare Act, and they are only employed for studies where lower species do not provide adequate models.

Class B dealers are individuals licensed by the USDA under the Animal Welfare Act to resell animals they did not breed themselves. Class A dealers are breeders who do raise the animals themselves. Class B dealers may purchase dogs and cats from sources such as municipal pounds, from individuals who bred and raised the animals, and from other licensed dealers. They are required to keep records on where they got each animal and to hold pound animals for a minimum period so that if an unwanted animal was actually a stray, the owner has time to reclaim it.

Animal statistics in 2010 (US data) - Dogs account of 0.25% and cats 0.08% of the total number of animals used.

Class B dealers used to provide a large number of cats and dogs for research because they were virtually the only source for older animals and for some breeds. Regrettably, some Class B dealers used practices that violated the Animal Welfare Act both in terms of how they acquired animals and how they treated them.  The National Academies of Science studied the specific areas of science where Class B dogs and cats were being used and concluded that NIH could develop alternate supply mechanisms to replace them. NIH decided the best way to facilitate the transition was to provide an initial outlay of funds so that Class A dealers could begin raising older dogs of the breeds required for scientific research. It is expected that these breeders will be able to produce the necessary animals by 2015.

After October 1, 2012, NIH-grant supported research can only use cats from the following sources: Class A dealers, privately owned research colonies, or client owned animals, such as animals that participate in veterinary clinical trials.  The same policy will apply to dogs in 2015 when the Class A breeding program is in full swing.

The transition of NIH-funded research away from the use of Class B dogs and cats is an example of how measures can be taken to correct ethical problems regarding the treatment of animals.  When ethical concerns exist, thoughtful and deliberate steps can address those concerns, while preserving important biomedical research projects.

Bill Yates and Alice Ra’anan.

Bill Yates is the Chair of American Physiological Society Animal Care and Experimentation Committee. Alice Ra’anan is Director of Science Policy for the American Physiological Society. The views expressed above are exclusively those of Bill Yates and Alice Ra’anan and do not necessarily represent those of their employers.

A Proposal for the Labeling of Medicines

In a recent poll conducted by Zogby, 2,100 adults in the U.S. were asked the following question.

Do you agree or disagree with medical and scientific research that requires lab animals?

The results showed  a similar outcome to that of other recent polls.

About 52% of the population approve of animal research in various degrees, about 27% disapprove in various degrees, 15% are neutral and 6% are unsure about their position.

Despite the many polls done on the subject it remains unclear on what grounds do some people object to the use of animals in science.

Is it perhaps that they find the work morally wrong?  Is it that they believe all living beings have the basic rights to liberty and freedom?

Some insight into these questions can be gained by asking the same group of people what would the do in the following scenario.

Suppose you suffer from a leaky heart valve, and that doctors say you have two years left.   You could have a valve replacement surgery that might save your life.  But, in order to obtain the replacement tissue necessary for a surgery, a pig must be killed.

Which of the following statements best reflects what you would do if faces with a similar situation?

Statement A: I would have the surgery.  I think it is ethical.
Statement B: I would have the surgery, but I think it is unethical.
Statement C: I would not have the surgery, but I think it is ethical.
Statement D: I would not have the surgery because I think it is unethical.

Here are the results from the same poll:

Now, if one believes animals have rights they surely ought to be respected.  If you believe a pig has the same basic rights to life and freedom as your neighbor, then you ought to refuse the surgery for the same reason that you would not kill your neighbor to save your own life.

However, only a mere 3% of those asked appear ready to act in a way consistent with such a position.  It is interesting to note that also about 3% of the US population are vegetarian, although most of them do it for health reasons and not ethical objections to the use of animals as food.

Thus, those that oppose research do not appear to do so because of belief that all living beings have the same basic rights to life as that of fellow humans.

Another small minority, 2%, would not have the surgery despite the fact they think such surgical intervention is ethical.  It would appear this group simply is uncomfortable with the notion that pig tissue would be implanted in their human hearts.

About 12% of the group would opt to save their lives despite having ethical objections.  It appears this group feels there is something inherently wrong in killing an animal to allow them to survive and yet, if faced with the situation they would nonetheless go ahead with the surgery.  Arguably, this group realizes that the pig is a living being that we owe moral concern, but that when human and animal lives are at stake, opting to save the human is morally permissible.  Alternatively, they may genuinely opt for behaving in an immoral fashion when it comes to saving their own lives.

Finally, the vast majority, 73% of them, will opt for the surgery without having any moral concerns whatsoever.   None at all.   That is roughly 3 out of 4 people in the US population.

A natural question is then why wouldn’t the same group, at the very least, be in favor of animal research that advances medical knowledge and human health?

One likely possibility is that they fail to see the direct link between research and the therapies and medicines that it produces.  They fail to see that the medicine that will save their lives next time they visit the emergency room will be, in all likelihood, the result of animal research.  They may wrongly perceive basic and translational research as two being completely different things.  The contribution of basic knowledge to human health may be lost in translation.

So, what can be done?

Aside from scientists and physicians reaching out to educate the public on this matters, we could begin by labeling each and every single medication that resulted from basic research in animals with such basic information.  Note that I am not talking about safety testing in animals — which is required by the law.  Instead, I am referring to medicines developed through the identification of molecular targets or the discovery of specific mechanisms with the use of animals in basic research.  In other words, I propose to label medicine as derived from animal research if it actually produced the knowledge that actually allowed scientists to understand how a particular therapy could be developed.

Shouldn’t the public be entitled to know where their medicines come from? Shouldn’t the public be entitled to understand the range of benefits produced by their tax dollars?

What do you think?

Ignorance or Deception?

Animal rights activists may want to start cooling down their engines.

Apparently, by 2050 we can expect the complete elimination of animal use in science.

At least, this is the prediction made by Dr. Andrew Rowan, Chief Scientific Officer of the Humane Society of the United States (HSUS) in a recent article that appeared in The Scientist.

The title of the piece was “Avoiding Animal Testing.  Advances in cell-culture technologies are paving the way to the complete elimination of animals from laboratories”.

The first half of the article focuses on the development and adoption of alternatives to the use of animals in toxicology.  Our public health officials and the FDA have long made the sensible decision to require any company that introduces new chemicals or drugs into the market to provide an initial experimental assessment of their potential toxicity to humans.

This use of animals for such safety screening is typically called animal testing.

Dr. Rowan correctly points out that advances in the development toxicology methods may allow us eventually to relax the regulations that require the use of animals in testing.  But he rapidly moves to insinuate such advances imply that by 2050 we could see the end of animal use in laboratories:

This overall decline in animal use can be attributed to the advent of novel technologies such as improved cell-culture systems and micro-analytic techniques; more sophisticated model systems; improved understanding of signaling and metabolic pathways; and a host of other new methods that allow scientists to answer important questions about the functioning of healthy and diseased tissues without subjecting whole animals to harmful procedures. With a 50 percent decline in animal research since 1975, we are roughly at the halfway point towards the complete elimination of animal research. Thus, we argue that, by 2050, we might finally see the last of animal use in the laboratory, particularly if all stakeholders put their minds to it.

First, the assertion that the total use of animals is systematically declining is not supported by the data.  The slide below, for example, was taken from a recent talk Dr. Rowan gave at the University of Wisconsin.  It shows the total number of animals used has been stable since the mid 80s, with the number of non-genetically modified (Non-GM, faint dashed line) animals decreasing and stabilizing in the 90s (see also data here), while the number of  genetically modified (GM) animals, which are largely mice, has been systematically increasing.

Second, even if correctly asserting that we can expect a diminished need for animals in toxicology testing, Dr. Rowan’s generalization of such trend from a such narrow field to all of biomedical research is groundless and misleading.

Let us be clear, our universities do not engage in animal testing, but in animal research.

What’s the difference?

Scientists are largely concerned with elucidating the basic mechanisms of biological processes in health and disease.  We want to study how cells in our bodies work, how they communicate, how they develop, how they age and how they die.   We want to understand how the brain, our immune system, and internal organs work and how they fail.  And so on…

Why is it critical we develop such an understanding?

Because without this knowledge there will be no hope to combat disease. Indeed, the mission of the National Institutes of Health (NIH) recognizes this fundamental fact in its opening statement,

NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life and reduce the burdens of illness and disability.

Implicit in such declaration is the acknowledgment that it is basic knowledge that drives advancements in human health and well-being.  Basic knowledge of nature is what drives progress.  This point is critical –   translational or applied research would not exist without basic knowledge as the raw material.  Without knowledge there would be nothing to translate nor apply.

Those that declare an imminent end to the use of animals in science are effectively implying that they envisage all basic knowledge needed will be acquired by a certain date, or that we will have methods that would allow us to proceed with studies non-invasively in human volunteers. Dr. Rowan’s statement that “Advances in cell-culture technologies are paving the way to the complete elimination of animals from laboratories” is nothing short of utter scientific nonsense.

Is it possible for Dr. Rowan to be ignorant of the role of animals in scientific research?  Could he legitimately be confused about the difference between safety testing on one hand and the development of therapies and basic research on the other?

This seems highly unlikely giving his academic credentials and the fact that he has served on IACUCs before.  In fact, another slide from his talk, shows him delineating these different uses of animals, and illustrating that animal testing for human safety accounts for merely ~25% of total animal use.

No, Dr. Rowan is not confused at all.  He knows what he is talking about.  This is unfortunate as one can only conclude his article is simply a misguided attempt to deceive the public about the fields in which we might realistically expect science to successfully replace animals in the near future.

And I emphasized science above for a good reason.

As difficult as it is for animal advocates to understand, scientists also believe we will see a day when we can eliminate the use of animals in all animal research.  And the day will arrive because of the hard work, progress and achievements of dedicated scientists, such as this one, and not because of deception of those that want to oppose animal research at all cost.

For HSUS to suggest that all animal research could be eliminated by 2050 is  flatly wrong from a scientific point of view, and utterly irresponsible from a public health perspective.

What Cost Savings? A Closer Look at the Great Ape Protection and Cost Savings Act of 2011

The status and future of chimpanzee research in the US are at the heart of much discussion lately in both scientific and public (also here and here) spheres.  A committee convened by the Institute of Medicine (IOM) to consider the issue held a number of meetings and is expected to report its findings to the NIH by the end of this year. Legislation to end great ape research, also introduced in 2007 and 2009 (H.R. 1513: Great Ape Protection and Cost Savings Act of 2011;  S. 810: Great Ape  Protection and Cost Savings Act of 2011; GAPA), was again introduced last Spring. This is the fourth of a series of posts aimed at encouraging thoughtful and fact-based consideration of the full range of complex issues associated with chimpanzee research and both short- and long-term responsibility for their welfare, care and housing. Posts include:

08/12/11: Facts must inform discussion of future of chimpanzee research.

10/13/11: Joseph M. Erwin, PhD Efforts to ban chimpanzee research are misguided.

11/21/11: A closer look at the Great Ape Protection Act.

Previous posts and other discussions of chimpanzee research have focused on ethical questions, animal welfare, and ongoing evaluation of the role chimpanzees do play, or should play, in scientific research.  These are the most important issues to address in discussion of the future of great apes in the U.S. At the same time, this year’s version of the Great Ape Protection Act has included a new focus, with addition of the phrase “and Cost Savings.”  The new language and the calculations given as basis for its assertions have received relatively little careful broad discussion or evaluation.

According to cost analysis for the legislation compiled by the Humane Society of the United States, the majority of cost-savings from GAPA – 76% – would result from ending federal grants for projects involving chimpanzees.  Of the “nearly $30 million saved annually” over $22 million reflects funds committed to support research projects that involve chimpanzees and are funded by the National Institutes of Health (NIH).

HSUS GAPA Cost Analysis

It appears that this number was arrived at by summing the cost of all NIH grants that involve chimpanzees, regardless of their topic or the types of activities in which the animals are engaged. Whether this number could reflect the total funds invested in what is commonly considered invasive research is not readily apparent. Some of these grants may involve noninvasive studies, others may be dedicated to studies that require as little as samples of DNA—something commonly done in human studies. It does appear that the underlying assumption for the cost analysis is a complete block on any NIH research grants that involve chimpanzees. (We welcome correction if this is not an assumption of the HSUS analysis or any cost analysis used to support the claims associated with GAPA.)

The remaining savings are projected from reduction in care costs if the animals were moved to sanctuaries.  Whether sanctuaries provide lower-cost care than research facilities is subject to some debate, in part because care costs vary across facilities. This is illustrated in the most recent data published by the National Center for Research Resources (NCRR) October 31, 2011 “Costs for Maintaining Humane Care and Welfare of Chimpanzees:”

Based on the most recent awards and payments, NIH is spending an average of $35 per day per chimpanzee in research facilities; $67.00 per day per chimpanzee in the research reserve facility at Alamogordo Primate Facility (APF); and $47 per day per chimpanzee in the federal sanctuary facility operated by Chimp Haven. The average for research facilities becomes $44 per day if the research reserve facility at APF is included. See Table 1 for detailed figures.”

The reasons for variance in costs are complex. Among other things, they do not reflect differences in housing, clinical care, or health status of the animals (e.g., older animals or animals with chronic health problems may require more expensive treatment and care). But overall, the numbers reported by NCRR show a rough equivalence in care costs at the federal sanctuary and many research facilities.

Table 1 “Costs for Maintaining Humane Care and Welfare of Chimpanzees, October 31, 2011

Research

Facility

# of Chimpanzees,
as of 10/31/11
(total)

NCRR cost*,
$M/year
(total)

NCRR cost,
$/animal/day,
(avg)

NIRC

117

1.23

28.8

K-CCMR

154

2.56

45.5

SNPRC (P51)

125

1.02

22.4

SNPRC (U42)

25

.047

56.3

Total

(421)

(5.3)

(34.5)

Research Reserve

Facility

# of Chimpanzees,
as of 10/31/11
(total)

NCRR cost*,
$M/year
(total)

NCRR cost,
$/animal/day,
(avg)

APF

173

4.25

67.4

Federal Sanctuary

Facility

# of Chimpanzees,
as of 10/31/11
(total)

NCRR cost*,
$M/year
(total)

NCRR cost,
$/animal/day,
(avg)

Chimp
Haven

119

2.03

46.7

What is not shown by these numbers or by most of the discussion of GAPA are the number of other issues that should accompany thoughtful consideration of the long-term care and housing of chimpanzees.  Dr. Joseph Erwin provided commentary on many of these in a previous guest post, among them concerns about ensuring the highest quality of care for the animals:

Most chimpanzees in scientific and educational institutions (research colonies and zoological gardens) live in spacious, social, and secure environments, where they are provided with excellent professional healthcare, and are afforded protection under the Animal Welfare Act, through inspection by the USDA, and publicly available reports of those inspections. The legislative ban would require removal of chimpanzees from decent facilities that were built at great public expense, and would deposit hundreds of chimpanzees in “sanctuaries” that provide no assurance of competent professional care, are not subject to Animal Welfare Act protection, and are not publicly transparent.”

One of the biggest unanswered (and virtually unmentioned in public spheres) questions surrounding the effects of this legislation is where it is that these chimpanzees would go? Is the intent that they would stay in current facilities? That new facilities would be constructed? While some animal rights groups have advocated for moving chimpanzees from their current research facilities to Chimp Haven, there is little information that would indicate that is a feasible option. Nor do the discussions of cost-savings and future plans include information about projected costs to build sufficient sanctuary space that could accommodate the number of animals currently housed in research facilities.

This is a non-trivial issue. For example, the publicly-available NCRR cost information informs us that the cost to construct the only federally-funded chimpanzee sanctuary, Chimp Haven, was $11.8 million. Chimp Haven houses 130 animals.  In other words, the initial construction cost was just over $90,000 per chimpanzee.

There are an additional 594 NIH-supported chimpanzees currently housed in research facilities. There are also hundreds of privately-owned chimpanzees. Thus, on even rough calculation based on the construction cost of Chimp Haven, it would appear that at least many millions of dollars would be required to extend the capacity for sanctuary housing to these animals. 

 

The cost, feasibility, and plan for constructing additional facilities that could provide care for these chimpanzees does not seem apparent in the cost calculations for the current legislation. Nor is it an issue raised much in public discussion.  It is a relatively easy thing to call for an end to chimpanzee research and to encourage public support by appealing to fiscal conservatism. What is far more challenging is to include consideration of real factors that significantly influence the outcomes for the animals, including an accurate assessment of where they can be housed, how best practices for care can be supported, real costs and dedicated sources of funding for long-term maintenance and facilities. Those details matter and deserve far more attention than they currently receive by those claiming to have chimpanzees’ welfare as the utmost priority.

Allyson J. Bennett

Guest post: Efforts to ban chimpanzee research are misguided.

The status and future of chimpanzee research in the US are at the heart of much discussion lately in both scientific and public spheres.  Discussion of human relationships with the great apes, their role in research—past, present, and future—and our responsibility for their continued care deserve thoughtful, well-informed consideration by both the scientific community and the public.  One of the primary goals of Speaking of Research is to contribute to dialogue about animal research and to provide factual information that is sometimes missing from the public conversation. In the case of chimpanzee research, their housing and care, and the GAPA legislation, it seems clear that there is uneven understanding of the current situation in the U.S., as well as lack of attention to the details and consequences of the proposed legislation were it to be enacted.  We have asked a number of primatologists involved in chimpanzee research, care and management to contribute to this discussion and begin a series on the issue here, with a guest post from Joseph M. Erwin, Ph.D. (UC Davis, 1974). 

Cheers,

Allyson

 

Efforts to ban chimpanzee research are misguided.

The author is a semi-retired consulting primatologist, whose career included service as a zoological curator, journal editor, university lecturer, and research associate at two major primate research centers. His most recent full-time position was as a VP and Division Director for an NIH research contract company, where he developed and implemented a program of environmental enrichment for nonhuman primates, designed innovative facilities, and engaged in research projects on aging in great apes and conservation biology field studies of primate populations in Indonesia. He has held university appointments in psychology, anthropology, child development, physiology, behavioral biology, and pathobiology, including affiliations in schools of human and veterinary medicine, as well as arts and sciences. He is currently a research professor of anthropology at George Washington University, Washington, D.C.  These comments were prompted by the continuing effort to ban scientific research involving chimpanzees. These are the opinions of the author and are not represented as policies or perspectives of any of his current or former clients or any organization with which he is affiliated. 

Dr. Joseph Erwin

You may not want to read this essay if you believe it is morally repugnant and unacceptable to involve human subjects in any kind of biomedical or behavioral research or clinical trials. If you do not believe that humans are animals and chimpanzees are our nearest biological kin, well, maybe these thoughts will not appeal to you. If, however, you recognize that humans have some obligation to discover and apply knowledge that can benefit our own and other species, you might want to read on.

Chimpanzees, like humans and other animals, deserve respect and due consideration. “Due consideration” implies that better decisions can be made if they are based on knowledge and understanding than on ignorance. The more we study chimpanzees (and humans), the better we can understand them, and the more likely our decisions are to benefit their health, well-being, and conservation, and the less likely we are to perform risky, harmful, or inhumane procedures. The current quality of care, refinement of procedures, and dramatic improvement in zoological and research facilities, all testify to the fact that scientific studies of chimpanzees in nature and captivity have changed the way we think about chimpanzees and how we can appropriately and humanely learn from them.

The continuing campaign to ban invasive research involving chimpanzees relies heavily on stories about chimpanzees who were treated in ways none of us would currently condone. Even in the exaggerated tone with which these stories are told, there is some truth. During the fifties, sixties, and even to some extent in the seventies and eighties, some chimpanzees were kept under very restrictive conditions and were subjected to tests and procedures that are no longer considered humane or acceptable and have been discarded.

By about thirty years ago, things had begun to change. Environments became less restrictive. The critical value of maternal rearing and social grouping was recognized. Scientists and facility managers began to insist on improved physical facilities. The value of information obtained noninvasively became clearer, including acceptance of the important role of behavioral monitoring and training to cooperate with caregivers, in contrast to the coercive methods that were previously thought to be essential.

But, the drum beat continues to ban “invasive” research involving chimpanzees, with claims that scientists in research facilities continually and routinely “torture” and “abuse” chimpanzees. “Invasive” has a nasty sound to it, and most of us would not approve of what is implied by the term. That serves those who use the term deceptively very well. First, they equate “invasive” with “torture,” “abuse,” and “vivisection.” Then they formally define the term in ways that would prohibit procedures we currently welcome for ourselves and our loved ones. The proposed research ban would criminalize procedures of which well-informed people of good conscience would certainly approve. The implications are far reaching, and they are not in the best interests of either humans or chimpanzees.

Most chimpanzees in scientific and educational institutions (research colonies and zoological gardens) live in spacious, social, and secure environments, where they are provided with excellent professional healthcare, and are afforded protection under the Animal Welfare Act, through inspection by the USDA, and publicly available reports of those inspections. The legislative ban would require removal of chimpanzees from decent facilities that were built at great public expense, and would deposit hundreds of chimpanzees in “sanctuaries” that provide no assurance of competent professional care, are not subject to Animal Welfare Act protection, and are not publicly transparent.

The proposed legislation to ban chimpanzee involvement in research is fundamentally dishonest. It claims to provide an improved quality of life for chimpanzees, without providing any verifiable assurance that it would actually do so. It also claims that the legislation would result in cost-savings for taxpayers. How would money be saved? Perhaps by provision of facilities that are less expensive because they are less secure or do not meet the standards required of zoos and universities; possibly by using well-meaning unpaid volunteers, rather than professionally qualified care and veterinary staff; and maybe by ensuring that scientific grant funding from government sources could not be used for any kind of research (no matter how humanely conducted). Elimination of public research grant funds is a major aspect of the proposed cost savings. The authors of the legislation are surely aware that the public will continue to be financially responsible for the long-term care of chimpanzees owned by the government, whether the chimpanzees are involved in productive research or not. Further, when well-meant sanctuaries financially fail, as some are sure to do (consider the examples fromEurope), US taxpayers will be on the hook to care for the chimpanzees. Neither humans nor chimpanzees would benefit from the restrictions imposed by this kind of excessive regulation that will not live up to its claims.

We continue to have much to learn from the careful and humane scientific study of humans and great apes, including chimpanzees. Noninvasive research (more accurately defined as the sorts of procedures that are ethically acceptable for human subjects and are based on due consideration of chimpanzee and human differences) can provide much mutually beneficial information on aging and life span development, genomic influences on health and behavior, best healthcare practices, preventive medicine, and the cognitive and emotional characteristics humans share with our sibling species. Do care about chimpanzees and work hard to ensure that they are well cared for. Don’t fall for legislation that is anti-science, anti-research, and ultimately harmful to humans and chimpanzees.

Joseph M. Erwin

Facts must inform discussion of future of chimpanzee research

The future of behavioral and biomedical research with chimpanzees is the focus of current discussion by a committee convened by the Institute of Medicine (IOM) at the request of the U.S. National Institutes of Health.  The second public meeting of the IOM convened Wednesday and Thursday. The meeting includes both experts on a broad range of topics that are investigated with chimpanzee studies, as well as members of the public, conservation, animal welfare and animal rights groups. The agenda and speaker list can be viewed here.

The charge of the committee is described as follows: 

Specifically, the committee will review the current use of chimpanzees for biomedical and behavioral research and:

  • Explore contemporary and anticipated biomedical research questions to determine if chimpanzees are or will be necessary for research discoveries and to determine the safety and efficacy of new prevention or treatment strategies. If biomedical research questions are identified:
  • Describe the unique biological/immunological characteristics of the chimpanzee that make it the necessary animal model for use in the types of research.
  • Provide recommendations for any new or revised scientific parameters to guide how and when to use these animals for research.
  • Explore contemporary and anticipated behavioral research questions to determine if chimpanzees are necessary for progress in understanding social, neurological and behavioral factors that influence the development, prevention, or treatment of disease.”

The IOM Committee and public meetings represent the kind of serious, thorough, and fact-based discussion that is essential to inform public decisions about animal research.

In striking contrast to this reasoned approach, however, was the emotional New York Times opinion piece from Representative Roscoe Bartlett (R-MD) that appeared on the opening day of the IOM’s latest meeting. Bartlett is a co-sponsor of legislation that would end much of the chimpanzee research in the United States, including studies like the recent tests of an Ebola virus vaccine intended to protect wild chimpanzees, and that proposes to move all chimpanzees to federally-subsidized sanctuaries. 

Bartlett’s op-ed opens with an anecdote about his experience with primate research in the 1960’s and his more recent conclusion that such research is no longer necessary because:

“… many new techniques are cheaper, faster and more effective, including computer modeling and the testing of very small doses on human volunteers. In vitro methods now grow human cells and tissues for human biomedical studies, bypassing the need for whole animals.”

Bartlett makes this assertion as though it were undisputed, whereas the reality is that the overwhelming majority of biomedical scientists, leading scientific organizations, and medical charities recognize that animal studies are crucial to current and future advances in medicine. In vitro and other research methods are nowhere near capable of replacing the use of animals in many areas of research, indeed our science news blog contains many examples of how animal research is helping to push the boundaries of scientific knowledge and medicine in emerging fields including tissue engineering, gene therapy, stem cell medicine, nanotech smart drugs and personalized medicine. In fact, the purpose of the IOM committee and hearings is to review evidence from a large number of experts with knowledge of the current state of knowledge and needs of the field. Bartlett does not have this expertise and it is unclear why he would make such an ill-informed statement, particularly in a venue like the NYT and particularly in light of the IOM committee meetings.

Furthermore, it is unclear that Bartlett is well-informed about current conditions for chimpanzees in research facilities in the US, or fully aware of the complex issues and challenges inherent in managing chimpanzee populations in either research setting, or the sanctuary settings that he advocates. Although he may have another source of knowledge, those that he references are his own research experience with primates in the NASA space program– which appears to have been prior to the 1966 passage of the Animal Welfare Act, videos, and the recently released movie, Project Nim, about research that took place decades ago.

As evidence of poor treatment of apes, the congressman makes the point that chimpanzees are sometimes darted to deliver anesthesia and “If you’ve seen video of a knockdown, you know it is clearly frightening and stressful.”  In fact, few people—including those working in primate laboratory research settings– would disagree with that statement, just as few would argue that continued efforts to improve management of captive chimpanzee populations are unnecessary. That is why major research facilities that house chimpanzees also have extensive behavioral management, training, and enrichment programs and research personnel who are committed to improving the animals’ welfare.  And included in the accomplishments of behavioral management and research personnel is progress in training animals for cooperative injections (e.g., voluntarily extending an arm to a trainer) in order to reduce stress.

Many people might imagine that the living conditions for chimpanzees in research facilities and sanctuaries are dramatically different. In reality both face similar challenges. For example, Bartlettimplies that things like “knock-downs” only occur at research facilities. In actuality, sanctuaries also require animals to be anesthetized for physical exams and health procedures, also have chimpanzees that are not trained for cooperative injection, and also employ darting. And while the housing conditions for chimpanzees in laboratories vary across facilities, Bartlett’s statement that “… even the mere confinement in laboratory cages deprives chimpanzees of basic physical, social and emotional sustenance” fails to acknowledge the more complex reality. Housing environments for laboratory chimpanzees can also be quite similar to those found in sanctuaries, including large spaces, social groups, complex climbing structures, and varied environmental enrichment.

The future of behavioral and biomedical research with chimpanzees merits serious and sustained discussion that is based in fact, advances in research technologies – ranging from new in vitro techniques, to genetically modified mice, through to studies in humans – mean that it is now time to consider what chimpanzee research is still necessary and ethically justifiable. One of the best avenues for understanding the complex issues that are involved in choices about both continued research and about how to best house and care for chimpanzees lies in listening not only to those who oppose research, but also in hearing from those currently engaged in research, husbandry, and animal welfare efforts within both sanctuary and research facilities.

The content of Representative Bartlett’s op-ed suggests that he may have allowed videos, movies, decades-old experience, and one very biased set of voices to inform his understanding of the current state of great ape research in the US.  If this is the case, we hope that Representative Bartlett listens to the IOM panel discussions and learns more about current conditions, ongoing research, and the full range of challenges involved in decisions about animal research.

                                            

Allyson J. Bennett

A paralyzed man stands again…thanks to animal research!

Yesterday an article appeared in the New York Times describing how scientists, supported by the National Institutes of Health and the Christopher and Dana Reeve Foundation, have used electrical stimulation of the lower spinal cord to enable a man who had been completely paralyzed below chest level to stand again,  and even to take steps on a treadmill. The good news has since spread around the world, being reported on the BBC, The Times of India, and Canadian TV

While the reports have – perhaps understandably –focused on the fact that this breakthrough has for the first time enabled a man with complete paralysis to stand and take a few steps, the Lancet paper describing this work also reports “improved autonomic function in bladder, sexual and thermoregulatory activity that has been of substantial benefit to the patient”. Such improvements are important as they have a huge impact on the overall wellbeing of a paralysis victim.

In this video Professor V. Reggie Edgerton of UCLA, who lead the team that undertook this study, describes the background to this study, and how discoveries made in both animal and clinical research made it possible.

 

Regular readers of the  Speaking of Research science blog may recognize his name, in October 2009 Prof. Edgerton wrote an article for Speaking of Research  in response to media coverage of a study he and his colleagues had published on the use of implanted electrodes to restore motor function in rats whose spinal cord had been severed, allowing the rats to stand and walk again. This study in rats – which can be read in full in PubMed Central – proved that in the absence of input from the brain due to the spinal cord being severed, electrical stimulation of the caudal segments of the spinal cord could enable the nerve circuits in the lower spine to use input from sensory nerves to control movement, and led directly to the clinical breakthrough reported yesterday.

But as is almost always the case this advance did not come from only one study, many years of basic research in both animals, intitally in cats – where it was first shown that an animal can walk despite the complete transection of the spinal cord -and later in rats, provided the scientific basis for this work, as Prof. Edgerton himself wrote in 2009:

 It has been characterized as a major breakthrough in facilitating the level of recovery of locomotion following a severe spinal cord injury. This in itself implies that these findings were the result of a single experiment with rats. But the reality is that these experiments were based on 100s of other experiments by not only my laboratory, but many other scientists. All of the previous animal experiments relevant to our understanding of the control of movement, involving many different species ranging at least from fish to humans, have contributed to the evolution of the concepts that underlie our most recent publication.”

Only time will tell what this study will mean for the millions paralyzed by spinal injuries – breakthroughs like this are better viewed as the end of the beginning than as the beginning of the end – and much further research will be needed to evaluate and improve this technique before it can be considered for widespread clinical use.

Firstly, the electrode arrray used in this study was relatively basic, but was FDA approved for use in humans and so appropriate for this early clinical study. Prof. Joel Burdick of Caltech, an author on this weeks Lancet study, is working to improve the design of the electrode arrays and the patterns of electrical stimulation applied to the spinal cord. Improvements in the way in which the electrical stimulation is delivered should increase the effectiveness of the technique.

A possible second improvement could be the addition of drugs that activate the locomotor nerve circuts. In the 2009 rat study some animals were treated with agonists for the 5-HT2A and 5-HT1A/7 serotonin receptors – on the basis of earlier research in mice and rats – in addition to receiving electrical stimulation, and it was found that this combination was considerably more effective than electrical stimulation alone. Unfortunately the serotonin agonists used in the 2009 rat study are still experimental and not approved for human use, and so could not be used in the clinical study reported in the Lancet. Hopefully 5-HT2A and 5-HT1A/7 serotonin agonists suitable for use in humans will soon be developed and evaluated in clinical trials, perhaps this weeks result will encourage investment in such drugs.

Many avenues towards repairing spinal cord damage or restoring function are currently being studied, and it is possible that this approach might be superseded in some, or even most, cases by advances in stem cell and regenerative medicine, and of course the various brain machine interfaces that we’ve discussed earlier may prove more appropriate for some conditions and patients.

 For today though, we offer Prof. Edgerton and his team our most heartfelt congratulations on an achievement that gives new hope to thousands.

Let’s also remember that this is but one of many examples of medical progress that animal rights activists would have prevented if they could have.  Fortunately, they did not succeed. It is up to us – medical researchers, health professionals and supporters of science and progress – to make sure it stays that way!

Paul Browne